Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Daré Bioscience Inc (DARE)
NASDAQ:DARE
Daré Bioscience (DARE) Stock Price & Analysis
1,741 Followers
DARE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.27 - $1.10
Previous Close$0.48
Volume318.49K
Average Volume (3M)360.84K
Market Cap
$42.77M
Enterprise Value$34.58M
Total Cash (Recent Filing)$13.90M
Total Debt (Recent Filing)$195.00K
Price to Earnings (P/E)-1.4
Beta1.06
Next Earnings
May 09, 2024EPS Estimate
-$0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding100,581,900
10 Day Avg. Volume170,268
30 Day Avg. Volume360,842
Standard Deviation0.22
R-Squared0.08
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)-21.10
Price to Sales (P/S)4.88
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue34.58
Enterprise Value/Gross Profit3.46
Enterprise Value/Ebitda-1.06
Forecast
1Y Price Target
$4.00Price Target Upside831.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Daré Bioscience News
Bulls Say, Bears Say
Bulls Say
Partnership And FundingDaré Bioscience's Ovaprene, a non-hormonal contraceptive, benefits from strong partnership support and funding from the NIH and Bayer, enhancing the likelihood of successful commercialization.
Product Launch And Revenue PotentialWith the commercial launch of Xaciato, Daré Bioscience stands to gain from double-digit royalties and up to $180M in potential milestone payments, marking a significant step in the company's revenue growth.
Regulatory MilestoneThe FDA has provided initial positive feedback for Daré Bioscience's sildenafil cream, indicating its potential to serve a broad patient population and advancing the product closer to market entry.
Bears Say
Financial PerformanceDaré filed its 10-K, reporting a net loss of ($30.1M) and ended the period with $10.5M in cash on the balance sheet.
Market AcceptanceIQVIA scripts for Xaciato have been growing but remain below expectations, indicating challenges in gaining formulary acceptance with payers.
Product EfficacySildenafil Cream did not achieve statistical significance for the co-primary endpoints in the exploratory study.
---
Ownership Overview
23.99%
Insiders
4.20% Mutual Funds
3.53% Other Institutional Investors
68.28% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
DARE FAQ
What was Daré Bioscience Inc’s price range in the past 12 months?
Daré Bioscience Inc lowest stock price was $0.27 and its highest was $1.10 in the past 12 months.
What is Daré Bioscience Inc’s market cap?
Currently, no data Available
When is Daré Bioscience Inc’s upcoming earnings report date?
Daré Bioscience Inc’s upcoming earnings report date is May 09, 2024 which is in 20 days.
How were Daré Bioscience Inc’s earnings last quarter?
Daré Bioscience Inc released its earnings results on Mar 28, 2024. The company reported -$0.07 earnings per share for the quarter, beating the consensus estimate of -$0.09 by $0.02.
Is Daré Bioscience Inc overvalued?
According to Wall Street analysts Daré Bioscience Inc’s price is currently Undervalued.
Does Daré Bioscience Inc pay dividends?
Daré Bioscience Inc does not currently pay dividends.
What is Daré Bioscience Inc’s EPS estimate?
Daré Bioscience Inc’s EPS estimate is -$0.06.
How many shares outstanding does Daré Bioscience Inc have?
Daré Bioscience Inc has 100,581,900 shares outstanding.
What happened to Daré Bioscience Inc’s price movement after its last earnings report?
Daré Bioscience Inc reported an EPS of -$0.07 in its last earnings report, beating expectations of -$0.09. Following the earnings report the stock price went down -10.909%.
Which hedge fund is a major shareholder of Daré Bioscience Inc?
Currently, no hedge funds are holding shares in DARE
---
Daré Bioscience Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (831.32% Upside)
$4.00 (831.32% Upside)
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-52.07%
12-Months-Change
Fundamentals
Return on Equity
-994.69%
Trailing 12-Months
Asset Growth
-51.44%
Trailing 12-Months
Company Description
Daré Bioscience Inc
Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert, and Roger L. Hawley in 2015 and is headquartered in San Diego, CA.
---
DARE Earnings Call
Q4 2024
0:00 / 0:00
---
DARE Stock 12 Months Forecast
Average Price Target
$4.00
▲(831.32% Upside)
Technical Analysis
Best Analysts Covering DARE
1 Year
1 Year Success Rate
7/23 ratings generated profit
1 Year Average Return
-3.36%
reiterated a buy rating 8 months ago
Copying Jason Kolbert's trades and holding each position for 1 Year would result in 30.43% of your transactions generating a profit, with an average return of -3.36% per trade.
---